IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.016
EU - Europa 1.843
AS - Asia 1.390
SA - Sud America 238
AF - Africa 195
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.688
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.004
SG - Singapore 482
HK - Hong Kong 435
IE - Irlanda 428
RU - Federazione Russa 418
CN - Cina 329
IT - Italia 252
SE - Svezia 242
BR - Brasile 215
CI - Costa d'Avorio 163
DE - Germania 132
UA - Ucraina 114
GB - Regno Unito 109
IN - India 66
FR - Francia 34
FI - Finlandia 22
BE - Belgio 18
MA - Marocco 18
KR - Corea 17
EE - Estonia 13
DK - Danimarca 11
TR - Turchia 9
CA - Canada 7
NL - Olanda 7
RO - Romania 7
AR - Argentina 6
JP - Giappone 6
AU - Australia 5
CO - Colombia 5
ES - Italia 5
AT - Austria 4
BG - Bulgaria 4
EC - Ecuador 4
ID - Indonesia 4
IL - Israele 4
IQ - Iraq 4
UZ - Uzbekistan 4
VN - Vietnam 4
AZ - Azerbaigian 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
KZ - Kazakistan 3
LU - Lussemburgo 3
MX - Messico 3
PK - Pakistan 3
PL - Polonia 3
PY - Paraguay 3
TN - Tunisia 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
BD - Bangladesh 2
EG - Egitto 2
IS - Islanda 2
KE - Kenya 2
LY - Libia 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
EU - Europa 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
IR - Iran 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LI - Liechtenstein 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
RS - Serbia 1
SA - Arabia Saudita 1
TH - Thailandia 1
Totale 11.688
Salva come PNG Salva come JPEG
Città #
Des Moines 1.471
Chandler 1.178
Fairfield 666
Ashburn 580
Hong Kong 435
Dublin 420
Wilmington 345
Boardman 312
Woodbridge 282
Houston 249
Seattle 246
Cambridge 214
Singapore 200
Jacksonville 199
Lawrence 167
Princeton 167
Abidjan 163
San Mateo 142
Ann Arbor 135
The Dalles 119
New York 116
San Diego 100
Moscow 91
Washington 73
Redmond 72
Pune 65
Los Angeles 52
London 41
Beijing 33
Dallas 32
Falls Church 31
Ancona 29
Shanghai 29
Wuhan 27
Guangzhou 24
Helsinki 21
Norwalk 19
São Paulo 19
Turin 19
Brussels 18
Jiaxing 14
Prescot 10
Forlì 9
Rio de Janeiro 9
Rome 9
Seoul 9
Brasília 8
Centro 8
Council Bluffs 7
Edinburgh 7
Fuzhou 7
Strasbourg 7
Wuxi 7
Bologna 6
Cagliari 6
Curitiba 6
Menlo Park 6
Nuremberg 6
Shenzhen 6
Southwark 6
Tolentino 6
Yiwu 6
Chicago 5
Fayetteville 5
Hounslow 5
Marche 5
Nanjing 5
Phoenix 5
Stockholm 5
Canosa di Puglia 4
Clifton 4
Kilburn 4
Marano di Valpolicella 4
Redwood City 4
Sofia 4
Tashkent 4
Viamão 4
Zhengzhou 4
Amsterdam 3
Baku 3
Buffalo 3
Frankfurt am Main 3
Gatchina 3
Guarulhos 3
Heze 3
Jinan 3
Jinhua 3
La Paz 3
Milan 3
New Bedfont 3
Pesaro 3
Portland 3
Porto Alegre 3
Prague 3
Saint Petersburg 3
Salvador 3
Santa Clara 3
Tokyo 3
Toronto 3
Torre Del Greco 3
Totale 8.903
Salva come PNG Salva come JPEG
Nome #
Designing novel immunocombinations in metastatic renal cell carcinoma 164
Immunotherapy in genitourinary cancers: Where are we going? 137
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 133
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 125
Are liver nested stromal epithelial tumors always low aggressive? 120
Microbiome and cancers, with focus on genitourinary tumors 113
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 108
Predicting future cancer burden in the United States by artificial neural networks 105
Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View 102
Exploring the Spectrum of Kidney Ciliopathies 102
Molecular diagnostics in uro-oncology 100
From undergraduate medical school student to visible pathologist 100
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 100
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 100
Is There a Role for Immunotherapy in Prostate Cancer? 97
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 96
Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule 94
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice 93
Pd-l1 inhibitors for the treatment of prostate cancer 93
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 93
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 92
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 92
Biomarkers of angiogenesis and clinical outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Randomized Phase III METEOR Trial 92
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 91
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 90
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 90
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 88
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype 88
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 88
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 88
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 88
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 87
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 86
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 86
Epigenetic modifications and modulators in prostate cancer 86
The human microbiota and prostate cancer: Friend or foe? 85
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 85
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 85
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 85
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 85
Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology 85
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 84
Immune checkpoint inhibitors for the treatment of bladder cancer 84
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 83
Molecular characterization of testicular germ cell tumors using tissue microdissection 83
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 83
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 82
Pathology and molecular updates in tumors of the prostate: towards a personalized approach. 81
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading 80
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 80
Variants of Bladder Cancer: The Pathologist's Point of View 80
Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer 79
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 79
Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins 79
Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871 79
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 78
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 77
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 77
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 76
Pathology without microscope: From a projection screen to a virtual slide 76
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 76
Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma 76
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 75
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice 75
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 75
Epigenetic modulations and lineage plasticity in advanced prostate cancer 75
Quick steps toward precision medicine in renal cell carcinoma 75
Immunotherapy and radiation therapy in renal cell carcinoma 75
Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance 75
Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy 75
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 75
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 74
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 73
Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view 73
The identification of immunological biomarkers in kidney cancers 73
Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading 73
Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC 73
Treating prostate cancer by antibody-drug conjugates 73
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 72
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 72
Emerging molecular technologies in genitourinary tumors 71
Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples 70
Renal Cell Carcinoma: genomic landscape and clinical implications 70
Editorial: Emerging biomarkers in genitourinary tumors 69
Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers 69
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer 69
Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now 69
Bone targeting agents in patients with metastatic prostate cancer: State of the art 69
Current and future perspectives of digital microscopy with fluorescence confocal microscope for prostate tissue interpretation: A narrative review 69
Biphasic Tumors of the Urogenital Tract: Selected Topics 68
Emerging molecular technologies in renal cell carcinoma: Liquid biopsy 67
Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589–97. Eur Urol 2018;74:525–6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization? 67
An update on investigational therapies that target STAT3 for the treatment of cancer 67
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 66
Exploring small extracellular vesicles for precision medicine in prostate cancer 66
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 66
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 66
Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies 66
Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme 66
Variants and new entities of bladder cancer 66
Totale 8.376
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.844
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.844
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202084 0 0 0 0 0 0 0 0 0 11 31 42
2020/20212.174 38 40 68 63 224 762 182 186 138 200 230 43
2021/20221.512 267 171 79 23 50 179 28 90 128 116 87 294
2022/20234.130 266 288 156 313 218 1.705 3 234 680 16 178 73
2023/20241.610 282 45 138 162 248 358 22 49 5 57 24 220
2024/20252.282 376 229 35 52 103 121 226 107 750 283 0 0
Totale 11.914